Unibest

Pharmaceutical intermediates

Roflumilast Intermediates

3 pharmaceutical intermediates for Roflumilast. Indication: Seborrheic dermatitis; Plaque psoriasis; Chronic obstructive pulmonary disease.

提交项目All intermediates

About Roflumilast

Originator
Takeda Pharmaceutical Inc
Indication
Seborrheic dermatitis; Plaque psoriasis; Chronic obstructive pulmonary disease
Approved Date
01/23/2018

Available intermediates

3 intermediates currently listed for Roflumilast. Request specifications, documentation or a quotation for any item below.

Roflumilast intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
4-Difluoromethoxy-3-hydroxybenzaldehyde151103-08-1//
4-(DIFLUOROMETHOXY)-3-(CYCLOPROPYLMETHOXY)-BENZALDEHYDE151103-09-2//
Methyl 4-(difluoroMethoxy)-3-hydroxybenzoate1159429-52-3//

Other programs under R

Ramelteon RegorafenibRelugolixRemdesivir RemibrutinibRepotrectinibResmetiromRevumenib

Building toward Roflumilast?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →